Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Glass Filters to Separate Tumor Cells in Blood Tests Can Speed Up Cancer Diagnosis

By LabMedica International staff writers
Posted on 04 May 2023

Early diagnosis is crucial for effective cancer treatment, as even brief delays can impact patient health and longevity. More...

One promising approach involves detecting circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs) released by tumors into blood samples. Analyzing these cells can provide direct information about cancer and predict disease progression in its early stages. However, the number of CTCs in cancer patients' blood is extremely low, necessitating improvements in capture and culture efficiency. Although glass is commonly used for cell culturing in laboratories, its application in CTC culturing has been underexplored. Researchers have now identified the optimal dimensions of glass filters for capturing CTCs and CAFs, demonstrating their ability to detect cells from lung cancer patients.

Researchers from Nagoya University (Nagoya, Japan) employed a unique method to visualize and capture cells on glass filters, which could lead to more efficient tumor cell culturing and improved cancer detection. They developed glass filters with various shapes and dimensions to determine which best captured CTCs and CAFs from lung cancer patients. Additionally, they created a system called FROG-CHIP to visualize the CTCs and CAFs captured on the glass filters. The researchers discovered that the most effective patterns for capturing CTCs, while allowing white blood cells to pass through, consisted of a circular pattern with a pitch of 20 micrometers and a diameter of eight micrometers. These dimensions provided high capture efficiency without retaining a significant number of white blood cells.

"These results suggest that our glass filters are useful as a tool for the early diagnosis of tumors," said Professor Tanaka of the Center for Low-Temperature Plasma Sciences. "Our findings would be useful at hospitals, clinics, and diagnostic testing companies to speed up cancer diagnosis."

Related Links:
Nagoya University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.